

PHASE III INNOVATOR MARKET AVAILABILITY

US PRODUCT

EU PRODUCT

Humira

Abbvie must approve all trial supply requests. It is likely that they will reject requests for biosimilar studies. Product can be purchased on the secondary market, however, it may not be possible to acquire more than 100-200 syringes per month. Expiration dating is typically 12-15 months from time of purchase.

Abbvie will not supply for trials. Product can be purchased on the secondary market, however, it may not be possible to acquire more than 1000 syringes per month. Expiration dating is typically 12-15 months from time of purchase.

Rituxan/Mabthera

Genentech will consider supplying for trials, but will require the sponsor name and some general trial/protocol information. Up to 1000 vials per month of either strength may be available on the secondary market. Expiration dating is typically 21-24 months from time of purchase.

Roche will supply for trials but will require the EudraCT number and a list of countries. Some product is available on the secondary market, however, it may only be possible to acquire a few hundred vials per month of either strength. Expiration dating is typically 18-24 months from time of purchase.

Remicade

Janssen will supply for trials and does not require study information. Expiration dating is typically 24-36 months from time of purchase.

Merck will supply for trials but will require the EudraCT number or other trial information in some markets. There is a substantial amount of product available on the secondary market. Expiration dating is typically 24-36 months from time of purchase.

Herceptin

Genentech will consider supplying for trials, but will require the sponsor name and some general trial/protocol information. Up to 1000 vials per month may be available on the secondary market. Expiration dating is typically 18-24 months from time of purchase.

Roche will supply for trials but will require the EudraCT number and a list of countries. Up to 1000 vials per month may be available on the secondary market. Expiration dating is typically 30-36 months from time of purchase.

Avastin

Genentech will consider supplying for trials, but will require the sponsor name and some general trial/protocol information. Up to 1000 vials per month of either strength may be available on the secondary market. Expiration dating is typically 12-18 months from time of purchase.

Roche will supply for trials but will require the EudraCT number and a list of countries. Some product is available on the secondary market, however, it may not be possible to acquire more than a few hundred vials per month of either strength. Expiration dating is typically 10-15 months from time of purchase.

Neulasta

Amgen will not supply for trials. 300-500 syringes per month may be available on the secondary market. Expiration dating is typically 21-27 months from time of purchase.

Amgen may support trials when purchasing from specific EU markets. Several hundred syringes per month may be available on the secondary market. Expiration dating is typically 21-24 months from time of purchase.

Neupogen

Amgen will not supply for trials. 200-300 packs of 10 syringes per month may be available on the secondary market. Expiration dating is typically 18-24 months from time of purchase.

Amgen may support trials when purchasing from specific EU markets. Several hundred syringes per month may be available on the secondary market. The presence of biosimilars of this product has limited supply in some markets. Expiration dating is typically 18-24 months from time of purchase.

Enbrel

Amgen will not supply for trials. 300-500 packs of 4 syringes per month may be available on the secondary market. Expiration dating is typically 18-24 months from time of purchase.

Pfizer will supply for trials but will require the EudraCT number and a list of countries in some markets. Several hundred packs of 4 per month may be available on the secondary market. Expiration dating is typically 18-24 months from time of purchase.